TG Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.

CEO

Michael Sean Weiss

CEOMichael Sean Weiss

Employees

338

Employees338

Headquarters

Morrisville, North Carolina

HeadquartersMorrisville, North Carolina

Founded

1993

Founded1993

Employees

338

Employees338

TGTX Key Statistics

Market cap

5.42B

Market cap5.42B

Price-Earnings ratio

90.22

Price-Earnings ratio90.22

Dividend yield

—

Dividend yield—

Average volume

1.64M

Average volume1.64M

High today

$34.42

High today$34.42

Low today

$33.50

Low today$33.50

Open price

$33.68

Open price$33.68

Volume

815.86K

Volume815.86K

52 Week high

$46.48

52 Week high$46.48

52 Week low

$21.65

52 Week low$21.65

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

14.3%

Sell

14.3%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.